PT-141 (Bremelanotide)

Overview

PT-141, known by its generic name bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist that was derived from the research peptide Melanotan II (MT-II). It was developed by Palatin Technologies and received FDA approval in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first melanocortin-based therapeutic to achieve regulatory approval.

The discovery of PT-141’s effects on sexual function was serendipitous. During early clinical trials of Melanotan II as a tanning agent in the 1990s at the University of Arizona, male subjects reported spontaneous penile erections as an unexpected side effect. This observation prompted systematic investigation of the melanocortin system’s role in sexual arousal, leading to the identification of the MC3R and MC4R receptor subtypes as mediators of central sexual response.

Structurally, PT-141 is the active carboxylic acid metabolite of Melanotan II, differing by the absence of the N-terminal acetyl and C-terminal amide groups. Despite this structural similarity, PT-141 was specifically optimized for its central nervous system effects on sexual function rather than melanogenesis, and it represents a fundamentally novel mechanism for addressing sexual dysfunction by acting through the central melanocortin system rather than through peripheral vascular mechanisms employed by phosphodiesterase type 5 (PDE5) inhibitors.

Mechanism of Action

PT-141 acts through a centrally mediated mechanism that distinguishes it from all previously approved treatments for sexual dysfunction. Its pharmacological target is the melanocortin receptor system in the hypothalamus and limbic structures.

MC4R Activation in the Hypothalamus

The primary mechanism of PT-141 involves agonism of melanocortin-4 receptors (MC4R) in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the hypothalamus. Activation of MC4R in these regions stimulates oxytocinergic neurons that project to the spinal cord via descending pathways. Oxytocin release at the level of the sacral parasympathetic nucleus (S2-S4) activates autonomic outflow to genital tissues, facilitating both physiological arousal responses (genital vasocongestion, lubrication) and the subjective experience of sexual desire through concurrent activation of limbic reward circuits.

MC3R Modulation

PT-141 also activates MC3R, which is expressed in the ventromedial hypothalamus and arcuate nucleus. While MC4R is considered the primary mediator of the sexual response, MC3R activation appears to contribute to the motivational and appetitive components of sexual behavior. Preclinical studies by Pfaus et al. demonstrated that MC3R signaling modulates dopaminergic neurotransmission in the mesolimbic reward pathway, potentially enhancing the incentive salience of sexual stimuli and contributing to the subjective experience of desire.

Distinction from Peripheral Mechanisms

Unlike PDE5 inhibitors (sildenafil, tadalafil) that act exclusively on peripheral vascular smooth muscle to enhance blood flow, PT-141 initiates the sexual response cascade at its neural origin. This central mechanism means PT-141 can influence both the desire/motivational component and the physiological arousal component of sexual response. The downstream signaling involves activation of endothelial nitric oxide synthase (eNOS) in genital vasculature, but this occurs as a consequence of central neural activation rather than direct pharmacological vasodilation.

Research Summary

The clinical development of PT-141 spans nearly two decades, with research initially focused on erectile dysfunction before pivoting to HSDD in women based on emerging clinical data.

Early Erectile Dysfunction Studies

Diamond et al. (2004), published in the International Journal of Impotence Research, conducted a double-blind, placebo-controlled study of intranasal PT-141 in 20 men with erectile dysfunction. The study demonstrated that PT-141 produced clinically significant erections as measured by RigiScan monitoring, with a dose-dependent response. Notably, PT-141 was effective in patients who had previously failed to respond to sildenafil, suggesting its central mechanism could bypass peripheral vascular limitations.

Female Sexual Dysfunction Research

Pfaus et al. (2007), published in Hormones and Behavior, provided comprehensive preclinical evidence that melanocortin agonists facilitated female sexual behavior in rodent models through central mechanisms involving the MPOA and ventromedial hypothalamus. These findings provided the scientific rationale for clinical investigation of PT-141 in female sexual dysfunction.

RECONNECT Phase III Trials

Kingsberg et al. (2019), published in Obstetrics & Gynecology, reported results from the two pivotal RECONNECT Phase III trials that supported FDA approval. Across both studies enrolling over 1,200 premenopausal women with HSDD, subcutaneous bremelanotide 1.75 mg administered on an as-needed basis significantly increased the number of satisfying sexual events (SSE) and improved scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared to placebo. The mean increase in SSE was approximately 1.0 event per month, with 35-38% of participants achieving a clinically meaningful response versus 28-31% with placebo.

Safety and Tolerability

Clayton et al. (2016), published in the Journal of Sexual Medicine, reported the long-term safety profile of bremelanotide from open-label extension studies. The most common adverse effect was nausea (approximately 40% of patients), which was typically mild, transient, and diminished with repeated dosing. Transient increases in blood pressure of 2-3 mmHg were observed within 12 hours of administration, leading to a contraindication in patients with uncontrolled hypertension. Importantly, no significant melanogenic effects were observed at the therapeutic dose, distinguishing it pharmacologically from its parent compound Melanotan II.

Dosing in Published Research

PT-141 is also known as bremelanotide and is an FDA-approved prescription medicine, sold as Vyleesi. According to the FDA-approved labeling, the dose is 1.75 mg injected subcutaneously into the abdomen or thigh, on an as-needed basis, at least 45 minutes before anticipated sexual activity, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Labeling limits use to one dose in any 24-hour period and no more than eight doses per month. These figures are drawn from FDA-approved prescribing information.

Safety and Side Effects

PT-141 (bremelanotide) is an FDA-approved drug, and its safety profile is reasonably well characterized. The most common adverse effects are nausea, which can be pronounced and is most likely with the first dose, along with flushing, headache, and injection-site reactions. Clinically important is its effect on the cardiovascular system: bremelanotide causes transient increases in blood pressure and reductions in heart rate after each dose, so it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and it should not be used by those at high cardiovascular risk. Use is limited to no more than one dose in any 24-hour period and no more than eight doses per month. Focal hyperpigmentation, including darkening of the face, gums, and breasts, has been reported, more often with frequent dosing or in people with darker skin, and may not fully resolve. Nausea and related effects led a meaningful minority of trial participants to discontinue treatment.

Current Research Status

Bremelanotide is an FDA-approved prescription medication, marketed as Vyleesi, approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its approval is specific to that population and indication; use outside it, including in men or for general sexual enhancement, is off-label and not supported by the approval. As a prescription drug it should be used under medical supervision, and material sold outside the regulated pharmacy supply chain is of uncertain identity, dose, and purity.

Frequently Asked Questions